Receptor-specific modulation of risk-based decision making by nucleus accumbens dopamine

Neuropsychopharmacology

Volumn 38, Issue 5, 2013, Pages 715-728

  Stopper, Colin M ^a   Khayambashi, Shahin ^a   Floresco, Stan B ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

D1 receptors; D3 receptors; neuroeconomics; probabilistic discounting; rat; ventral striatum

Indexed keywords

3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BROMOCRIPTINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ETICLOPRIDE; QUINPIROLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DECISION MAKING; DOPAMINE BRAIN LEVEL; DRUG EFFECT; DRUG MECHANISM; MALE; NEGATIVE FEEDBACK; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROBABILITY; RAT; REWARD;

ANIMALS; ATTENTION; CONDITIONING, OPERANT; DECISION MAKING; DISCRIMINATION (PSYCHOLOGY); DOPAMINE; DOPAMINE AGENTS; MALE; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; PROBABILITY; RATS; RATS, LONG-EVANS; RECEPTORS, DOPAMINE; REWARD; RISK-TAKING;

EID: 84875212582     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.240     Document Type: Article

References (59)

1. Aberman JE, Ward SJ, Salamone JD (1998). Effects of dopamine antagonists and accumbens dopamine depletions on timeconstrained progressive-ratio performance. Pharmacol Biochem Behav 61: 341-348.
2. Ahlskog JE (2011). Pathological gambling behaviors provoked by dopamine agonist therapy of Parkinson's disease. Physiol Behav 104: 168-172.
3. Bari A, Eagle DM, Mar AC, Robinson ES, Robbins TW (2009). Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats. Psychopharmacology 205: 273-283.
4. Bari AA, Pierce RC (2005). D1-like and D2 dopamine receptor antagonists administered into the shell subregion of the rat nucleus accumbens decrease cocaine, but not food, reinforcement. Neuroscience 135: 959-968.
5. Bachtell RK, Whisler K, Karanian D, Self DW (2005). Effects of intra-nucleus accumbens shell administration of dopamine agonists and antagonists on cocaine-taking and cocaine-seeking behaviors in the rat. Psychopharmacology 183: 41-53.
6. Bergh C, Eklund T, Söderston P, Nordin C (1997). Altered dopamine function in pathological gambling. Psychol Med 27: 473-475.
7. Berglind WJ, Case JM, Parker MP, Fuchs RA, See RE (2006). Dopamine D1 or D2 receptor antagonism within the basolateral amydala differentially alters the acquisition of cocaine-cue associations necessary for cue-induced reinstatement of cocaine-seeking. Neuroscience 137: 699-706.
8. Besson M, Belin D, McNamara R, Theobald DE, Castel A, Beckett VL et al (2010). Dissociable control of impulsivity in rats by dopamine d2/3 receptors in the core and shell subregions of the nucleus accumbens. Neuropsychopharmacology 35: 560-569.
9. Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B, Schwartz JC (1991). Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 564: 203-219.
10. Bristow LJ, Cook GP, Gay JC, Kulagowski JJ, Landon L, Murray F et al (1996). The behavioural and neurochemical profile of the putative dopamine D3 receptor agonist, (\+)-PD 128907, in the rat. Neuropharmacology 35: 285-294.
11. Cardinal RN, Howes NJ (2005). Effects of lesions of the nucleus accumbens core on choice between small certain rewards and large uncertain rewards in rats. BMC Neurosci 6: 37.
12. Cardinal RN, Robbins TW, Everitt BJ (2000). The effects of d-amphetamine, chlordiazepoxide, alpha-flupenthixol and behavioral manipulations on choice of signaled and unsignalled delayed reinforcement in rats. Psychopharmacology 152: 362-375.
13. Chen G, Kittler JT, Moss SJ, Yan Z (2006). Dopamine D3 receptors regulate GABAA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens. J Neurosci 26: 2513-2521.
14. Cools R, Lewis SJ, Clark L, Barker RA, Robbins TW (2007). L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 32: 180-189.
15. Cousins MS, Wei W, Salamone JD (1994). Pharmacological characterization of performance on a concurrent lever pressing/feeding choice procedure: effects of dopamine antagonist, cholinomimetic, sedative, and stimulant drugs. Psychopharmacology 116: 529-537.
16. Dang D, Cunnington D, Swieca J (2011). The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. Clin Neuropharmacol 34: 66-70.
17. Floresco SB, Block AE, Tse MT (2008). Inactivation of the medial prefrontal cortex of the rat impairs strategy set-shifting, but not reversal learning, using a novel, automated procedure. Behav Brain Res 190: 85-96.
18. Floresco SB (2007). Dopaminergic regulation of limbic-striatal interplay. J Psychiatry Neurosci 32: 400-411.
19. Floresco SB, Blaha CD, Yang CR, Phillips AG (2001). Dopamine D1 and NMDA receptors mediate potentiation of basolateral amygdala-evoked firing of nucleus accumbens neurons. J Neurosci 21: 6370-6376.
20. Floresco SB, Phillips AG (1999). Dopamine and hippocampal input to the nucleus accumbens play an essential role in the search for food in an unpredictable environment. Psychobiology 27: 227-286.
21. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag AS (2007). Pathological gambling in Parkinson's disease and the recurrent emergence of pathological gambling. Cogn Behav Neurol 20: 11-14.
22. Ghods-Sharifi S St., Onge JR, Floresco SB (2009). Fundamental contribution by the basolateral amygdala to different forms of decision making. J Neurosci 29: 5251-5259.
23. Gingrich B, Liu Y, Cascio C, Wang Z, Insel TR (2000). Dopamine D2 receptors in the nucleus accumbens are important for social attachment in female prairie voles (Microtus ochrogaster). Behav Neurosci 114: 173-183.
24. Goto Y, Grace AA (2005). Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nat Neurosci 8: 805-812.
25. Grace AA, Rosenkranz JA (2002). Regulation of conditioned responses of basolateral amygdala neurons. Physiol Behav 77: 489-493.
26. Haluk DM, Floresco SB (2009). Ventral striatal dopamine modulation of different forms of behavioral flexibility. Neuropsychopharmacology 34: 2041-2052.
27. Harvey J, Lacey MG (1997). A postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release. J Neurosci 17: 5271-5280.
28. Jenkins OF, Jackson DM (1986). Bromocriptine enhances the behavioural effects of apomorphine and dopamine after systemic or intracerebral injection in rats. Neuropharmacology 25: 1243124-1243129.
29. Knutson B, Adams CM, Fong GW, Hommer D (2001a). Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J Neurosci 21: RC159.
30. Knutson B, Fong GW, Adams CM, Varner JL, Hommer D (2001b). Dissociation of reward anticipation and outcome with eventrelated fMRI. Neuroreport 12: 3683-3687.
31. Knutson B, Rick S, Wimmer GE, Prelec D, Lowenstein G (2007). Neural predictors of purchases. Neuron 53: 147-156.
32. Kuhnen CM, Knutson B (2005). The neural basis of financial risk taking. Neuron 47: 763-770.
33. Lader M (2008). Antiparkinsonian medication and pathological gambling. CNS Drugs 22: 407-416.
34. Levant B (1998). Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res 800: 269-274.
35. Matthews SC, Simmons AN, Lane SD, Paulus MP (2004). Selective activation of the nucleus accumbens during risk-taking decision making. Neuroreport 15: 2123-2127.
36. Nicola SM, Surmeier J, Malenka RC (2000). Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci 23: 185-215.
37. Nicola SM (2007). The nucleus accumbens as part of a basal ganglia action selection circuit. Psychopharmacology 191: 521-550.
38. Nicola SM, Malenka RC (1997). Dopamine depresses excitatory and inhibitory synaptic transmission by direct mechanisms in the nucleus accumbens. J Neurosci 17: 5697-5710.
39. Nowend KL, Arizzi M, Carlson BB, Salamone JD (2001). D1 or D2 antagonism in nucleus accumbens core or dorsomedial shell suppresses lever pressing for food but leads to compensatory increases in chow consumption. Pharmacol Biochem Behav 69: 373-382.
40. Ouagazzal AM, Creese I (2000). Intra-accumbens infusion of D(3) receptor agonists reduces spontaneous and dopamine-induced locomotion. Pharmacol Biochem Behav 67: 637-645.
41. Pattij T, Janssen MC, Vanderschuren LJ, Schoffelmeer AN, van Gaalen MM (2007). Involvement of dopamine D1 and D2 receptors in the nucleus accumbens core and shell in inhibitory response control. Psychopharmacology 191: 587-598.
42. Paxinos G, Watson C (2005). The Rat Brain in Stereotaxic Coordinates, 4th Edn. Academic Press: San Diego (CA).
43. Pennartz CMA, Groenewegen HJ, Lopes Da Silva FH (1994). The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. Prog Neurobio 42: 719-761.
44. Pezze MA, Dalley JW, Robbins TW (2007). Differential roles for dopamine D1 and D2 receptors in the nucleus accumbens in attentional performance on the five-choice serial reaction time task. Neuropsychopharmacology 32: 273-283.
45. Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G et al (1995). Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther 275: 1355-1366.
46. Quickfall J, Sucherowsky O (2007). Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord 13: 535-536.
47. Roberts C, Cummins R, Gnoffo Z, Kew JN (2006). Dopamine D3 receptor modulation of dopamine efflux in the rat nucleus accumbens. Eur J Pharmacol 534: 108-114.
48. Salamone JD, Arizzi MN, Sandoval MD, Cervone KM, Aberman JE (2002). Dopamine antagonists alter response allocation but do not suppress appetite for food in rats: contrast between the effects of SKF 83566, raclopride, and fenfluramine on a concurrent choice task. Psychopharmacology 160: 371-380.
49. Sautel F, Griffon N, Lévesque D, Pilon C, Schwartz JC, Sokoloff P (1995). A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport 6: 329-332.
50. Schmidt HD, Anderson SM, Pierce RC (2006). Stimulation of D1-like or D2 dopamine receptors in the shell, but not the core, of the nucleus accumbens reinstates cocaine-seeking behaviour in the rat. Eur J Neurosci 23: 219-228.
51. St Onge JR, Abhari H, Floresco SB (2011). Dissociable contributions by prefrontal D1 and D2 receptors to risk-based decision making. J Neurosci 31: 8625-8633.
52. St Onge JR, Ahn S, Phillips AG, Floresco SB (2012a). Dynamic fluctuations in dopamine efflux in the prefrontal cortex and nucleus accumbens during risk-based decision making. J Neurosci 32: 16880-16891.
53. St Onge JR, Chiu YC, Floresco SB (2010). Differential effects of dopaminergic manipulations on risky choice. Psychopharmacology 211: 209-221.
54. St Onge JR, Floresco SB (2009). Dopaminergic modulation of riskbased decision-making. Neuropsychopharmacology 34: 681-697.
55. St Onge JR, Floresco SB (2010). Prefrontal cortical contribution to risk-based decision making. Cereb Cortex 20: 1816-1828.
56. St Onge JR, Stopper CM, Zahm DS, Floresco SB (2012b). Separate prefrontal-subcortical circuits mediate different components of risk-based decision making. J Neurosci 32: 2886-2899.
57. Stopper CM, Floresco SB (2011). Contributions of the nucleus accumbens and its subregions to different aspects of risk-based decision making. Cogn Affect Behav Neurosci 11: 97-112.
58. Sugam JA, Day JJ, Wightman RM, Carelli RM (2012). Phasic nucleus accumbens dopamine encodes risk-based decisionmaking behavior. Biol Psychiatry 71: 199-205.
59. Zack M, Poulos CS (2004). Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers. Neuropsychopharmacology 29: 195-207.